Document is current
Any future updates will be listed below
-
Authors
Song, Seungwon
Jeong, Jaewook
Yum, Jungyon
Kim, Kyung Min
Chu, Min Kyung
-
Funding
Funding for this research was provided by:
Ministry of Health and Welfare (HV22C0106)
National Research Foundation of Korea (2022R1A2C1091767)
- License Information
-
More Information
Article History
Received: 8 March 2025
Accepted: 4 September 2025
First Online: 29 September 2025
Declarations
:
: The CHASE study was approved by the Institutional Review Board at Severance Hospital, Yonsei University (approval no. 2020–0034 − 001). All participants provided written informed consent before participating. The study procedures adhered to the ethical standards outlined in the Declaration of Helsinki and its subsequent amendments, ensuring compliance with ethical guidelines for research involving human participants.
: The authors declare the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: MKC was a site investigator for a multicenter trial sponsored by Biohaven Pharmaceuticals, Allergan Korea, and Ildong Pharmaceutical Company. He has received lecture honoraria from Eli Lilly and Company, Handok-Teva, and Ildong Pharmaceutical Company over the past 24 months. He received grants from the Yonsei University College of Medicine (6-2021-0229), the Korea Health Industry Development Institute (HV22C0106), and a National Research Foundation of Korea grant from the Korean Government (MSIT; 2022R1A2C1091767). The other authors declare no conflicts of interest.
